LOXL2 drives MSC differentiation into CAFs and contributes to MPN progression by modulating peripheral stromal cells; LOX inhibitors and LOXL2 inhibitors are being tested for targeted MPN treatment (35–37). The gene discussed is LOX; the disease is myeloproliferative neoplasm.